We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

69 hedge funds and large institutions have $152M invested in Lineage Cell Therapeutics in 2015 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 22 increasing their positions, 12 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

439% more call options, than puts

Call options by funds: $2.58M | Put options by funds: $478K

250% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 4

83% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 12

33% more capital invested

Capital invested by funds: $114M → $152M (+$37.9M)

17% more funds holding

Funds holding: 59 → 69 (+10)

0.07% more ownership

Funds ownership: 45.47% → 45.54% (+0.07%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
69
Holders Change
+10
Holders Change %
+16.95%
% of All Funds
1.84%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
14
Increased
22
Reduced
12
Closed
4
Calls
$2.58M
Puts
$478K
Net Calls
+$2.1M
Net Calls Change
+$2.23M

Top Buyers

1
CC
CQS Cayman
Cayman Islands
+$589K
2
Citadel Advisors
Citadel Advisors
Florida
+$348K
3
FM
Family Management
New York
+$279K
4
BIT
BlackRock Institutional Trust
California
+$219K
5
State Street
State Street
Massachusetts
+$219K

Top Sellers

1
DWM
Destination Wealth Management
California
-$2.22M
2
Morgan Stanley
Morgan Stanley
New York
-$283K
3
Group One Trading
Group One Trading
Illinois
-$159K
4
SCP
Seizert Capital Partners
Michigan
-$73K
5
Bank of New York Mellon
Bank of New York Mellon
New York
-$48.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
ProShare Advisors
51
ProShare Advisors
Maryland
$50K -$4.81K -1,389 -10%
Wells Fargo
52
Wells Fargo
California
$31K +$8.18K +2,363 +45%
Creative Planning
53
Creative Planning
Kansas
$26K +$8.57K +2,478 +61%
Fifth Third Bancorp
54
Fifth Third Bancorp
Ohio
$21K – – –
Citigroup
55
Citigroup
New York
$17K -$31.5K -9,102 -69%
UBS Group
56
UBS Group
Switzerland
$13K -$11.5K -3,328 -51%
Royal Bank of Canada
57
Royal Bank of Canada
Ontario, Canada
$13K +$1K +290 +9%
PIA
58
Peachtree Investment Advisors
Georgia
$10K – – –
BNP Paribas Financial Markets
59
BNP Paribas Financial Markets
France
$6.21K +$5.16K +1,491 +1,080%
Bank of Montreal
60
Bank of Montreal
Ontario, Canada
$5K +$1.07K +309 +31%
VIA
61
Vantage Investment Advisors
Pennsylvania
$5K +$2.14K +619 +100%
BlackRock
62
BlackRock
New York
$5K +$4.48K +1,295 New
LTFS
63
Ladenburg Thalmann Financial Services
Florida
$2K – – –
HF
64
Hoxton Financial
West Virginia
$1K – – –
PSI
65
Pinnacle Summer Investments
Virginia
$1K – – –
Manulife (Manufacturers Life Insurance)
66
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$198 -$5.88K -1,700 -3%
DWM
67
Destination Wealth Management
California
– -$2.22M -736,772 Closed
SCP
68
Seizert Capital Partners
Michigan
– -$73K -24,161 Closed
CS
69
Credit Suisse
Switzerland
– -$40K -13,134 Closed
LS
70
Lupo Securities
Illinois
– -$4.43K -1,472 Closed
GT
71
Glenmede Trust
Pennsylvania
– +$3 +1 New
TRCT
72
Tower Research Capital (TRC)
New York
– +$138 +40 New
1 2
3

LCTX Hedge Fund Activity: Q1 2015 in Review

69 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q1 2015, worth a combined $152M — up 33% from $114M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new LCTX positions and 4 closed out — a net gain of 10 holders — while 22 added to existing stakes and 12 trimmed.

The largest buyer was CQS Cayman, opening a new position worth an estimated $589K. The largest seller was Destination Wealth Management, exiting entirely with an estimated $2.22M sold.

  • 69 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q1 2015, up from 59 in Q4 2014.
  • Funds reported $152M of Lineage Cell Therapeutics stock for Q1 2015, up 33% quarter-over-quarter.
  • 14 funds opened new Lineage Cell Therapeutics positions in Q1 2015 and 4 closed out, a net change of +10 holders.
  • The largest Lineage Cell Therapeutics buyer in Q1 2015 was CQS Cayman, an estimated $589K added.
  • The largest Lineage Cell Therapeutics seller in Q1 2015 was Destination Wealth Management, an estimated $2.22M sold.

Based on aggregated 13F filings for Q1 2015.